Assessment of the Nutritional Status of Children and Adolescents With Malignancies
19. september 2014 opdateret af: University of Hohenheim
Assessment of the Nutritional Status of Children and Adolescents With Malignancies Aged Between 0-18, Based on BMI Percentiles and Standard Deviation Scores, at Diagnosis, During Treatment, and During Two Years Follow-up
The main objective of this study was the assessment of the nutritional status of children and adolescents aged between 0-18 with malignancies based on BMI percentiles and standard deviation scores, at diagnosis, during treatment and during a period of two years after the end of therapy.
Studieoversigt
Status
Afsluttet
Betingelser
Detaljeret beskrivelse
Children and adolescents suffering from malignancies often show malnutrition. Malnutrition, defined as a deficiency or an excess of energy, is associated with an increased risk of comorbidities, reduced survival rates, higher relapse rates, and worse treatment response.
The present retrospective study assessed the nutritional status of children and adolescents, suffering from nine different kinds of cancer, based on BMI percentiles and standard deviation scores. Anthropometric data were recorded from clinical charts and an assessment of the nutritional status was made at the beginning of treatment, during the course of therapy and during a follow-up period of two years. The influence of treatment-related characteristics, the duration of therapy, and the occurrence of a relapse or progress during therapy on the nutritional status were examined.
Undersøgelsestype
Observationel
Tilmelding (Faktiske)
135
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
Ikke ældre end 18 år (Barn, Voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Children and adolescents, treated for one of the following diseases: lymphoma, germ cell tumor, nephroblastoma, soft tissue sarcoma, neuroblastoma, Ewing sarcoma, brain tumor, or acute lymphoblastic leukemia (ALL)/acute myeloid leukemia (AML)
Beskrivelse
Inclusion Criteria:
- children and adolescents treated at the Olgahospital Stuttgart for one of the nine different cancer types
- treated according to a study protocol of the Society of Pediatric Oncology and Hematology (GPOH), with modifications only allowed within the therapeutic protocol
- time period between diagnosis and start of treatment less than 28 days
- age younger than 18
Exclusion Criteria:
- severe underlying disease, which exerts a strong influence on weight and/or height
- patients whose clinical record does not state any weight and/or height
- diseases which are not considered as malignant because of the state or biology
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Tidsperspektiver: Tilbagevirkende kraft
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Nutritional status at diagnosis
Tidsramme: Within the month of diagnosis
|
To assess the nutritional status height and weight were recorded from patient charts to calculate the BMI percentile (Body Mass Index percentile) and the BMI-SDS (Body Mass Index-Standard Deviation Score)
|
Within the month of diagnosis
|
|
Change in nutritional status during treatment
Tidsramme: Every month during the treatment period (average treatment period 11 months)
|
To assess the nutritional status height and weight were recorded from patient charts to calculate the BMI percentile and the BMI-SDS
|
Every month during the treatment period (average treatment period 11 months)
|
|
Change in nutritional status during follow-up
Tidsramme: Once in a period of three months during two years follow-up
|
To assess the nutritional status height and weight were recorded from patient chart to calculate the BMI percentile and the BMI-SDS
|
Once in a period of three months during two years follow-up
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical picture
Tidsramme: Within the month of diagnosis
|
Kind of cancer (lymphoma, germ cell tumor, nephroblastoma, soft tissue sarcoma, neuroblastoma, Ewing sarcoma, brain tumor, acute lymphoblastic leukemia (ALL)/acute myeloid leukemia (AML)), recorded from patient chart
|
Within the month of diagnosis
|
|
Age (years)
Tidsramme: Within the month of diagnosis
|
Age in years, recorded from patient chart
|
Within the month of diagnosis
|
|
Treatment period (months)
Tidsramme: Patients were followed for the duration of their treatment period. Average treatment period 11 months
|
Time from start until the end of treatment, recorded from patient chart
|
Patients were followed for the duration of their treatment period. Average treatment period 11 months
|
|
Incidence of nutritional interventions
Tidsramme: Patients were followed for the incidence of a nutritional intervention within the treatment period (average treatment period 11 months)
|
Application of parenteral nutrition or gastric tube (yes/no), recorded from patient chart
|
Patients were followed for the incidence of a nutritional intervention within the treatment period (average treatment period 11 months)
|
|
Infection
Tidsramme: Patients were followed for the occurence of an infection within the treatment period (average treatment period 11 months)
|
Occurence of an infection (yes/no), recorded from patient chart
|
Patients were followed for the occurence of an infection within the treatment period (average treatment period 11 months)
|
|
Fever
Tidsramme: Patients were followed for the occurence of fever within the treatment period (average treatment period 11 months)
|
Occurence of fever (yes/no), recorded from patient chart
|
Patients were followed for the occurence of fever within the treatment period (average treatment period 11 months)
|
|
Administration of antibiotics
Tidsramme: Patients were followed for the occurence of an administration of antibiotics within the treatment period (average treatment period 11 months)
|
Administration of antibiotics (yes/no), recorded from patient chart
|
Patients were followed for the occurence of an administration of antibiotics within the treatment period (average treatment period 11 months)
|
|
Diarrhea
Tidsramme: Patients were followed for the occurence of diarrhea within the treatment period (average treatment period 11 months)
|
Occurence of diarrhea (yes/no), recorded from patient chart
|
Patients were followed for the occurence of diarrhea within the treatment period (average treatment period 11 months)
|
|
Mucositis
Tidsramme: Patients were followed for the occurence of mucositis within the treatment period (average treatment period 11 months)
|
Occurence of mucositis (yes/no),recorded from patient chart
|
Patients were followed for the occurence of mucositis within the treatment period (average treatment period 11 months)
|
|
Nausea
Tidsramme: Patients were followed for the occurence of nausea within the treatment period (average treatment period 11 months)
|
Occurence of nausea (yes/no), recorded from patient chart
|
Patients were followed for the occurence of nausea within the treatment period (average treatment period 11 months)
|
|
Constipation
Tidsramme: Patients were followed for the occurence of constipation within the treatment period (average treatment period 11 months)
|
Occurence of constipation (yes/no), recorded from patient chart
|
Patients were followed for the occurence of constipation within the treatment period (average treatment period 11 months)
|
|
Relapse/Progress
Tidsramme: Patients were followed for the occurence of a relapse/progress within the treatment period (average treatment period 11 months) and follow-up (two years)
|
Occurence of a relapse/progress (yes/no), recorded from patient chart
|
Patients were followed for the occurence of a relapse/progress within the treatment period (average treatment period 11 months) and follow-up (two years)
|
|
Kind of treatment
Tidsramme: Patients were followed for the kind of treatment they received wihin the treatment period (average treatment period 11 months)
|
Kind of treatment (chemotherapy, operation, Radiation), recorded from Patient chart
|
Patients were followed for the kind of treatment they received wihin the treatment period (average treatment period 11 months)
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. juni 2013
Primær færdiggørelse (Faktiske)
1. januar 2014
Studieafslutning (Faktiske)
1. januar 2014
Datoer for studieregistrering
Først indsendt
17. september 2014
Først indsendt, der opfyldte QC-kriterier
19. september 2014
Først opslået (Skøn)
22. september 2014
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
22. september 2014
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
19. september 2014
Sidst verificeret
1. september 2014
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- EM-13
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .